Eikon Therapeutics bags another Merck exec to its team

California-based biotech Eikon Therapeutics announced the appointment of Kenneth Frazier as an independent director effective April 1, 2022.

Among the world’s most admired global business leaders, Mr Frazier remains as executive chairman and former chief executive of Merck & Co (NYSE: MRK) having stepped down from that post in February 2021, and is chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil (NYSE: XOM).

“It is a great honor to welcome Ken as our first independent board member,” said Roger M. Perlmutter, chief executive and chairman of Eikon Therapeutics, adding: “Our company will benefit enormously from Ken’s deep knowledge of the pharmaceutical industry, and from his broad perspective on matters of business, law, and the needs of society. Beyond all this, Ken’s advocacy for social justice will inspire every board member, every executive, and indeed every employee of Eikon Therapeutics.”